Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 57.37

+0.9%

Dec 8 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who started this subject	10/7/2000 1:47:52 PM
From: nigel bates	Read Replies (1) of 52153

From SNP article on the news thread - Message 14532045 "Citing Orchid's "superior SNP testing technology" and forecasting a 35% revenue growth rate, Chovov values Orchid stock at 52 times year 2002 revenue, generating a target price of $60.... ...To date, Incyte holds over 30,000 royalty licenses, and these might be considered, Chovov suggests, "call options" on potential drugs... Chovov values Incyte in terms of its technology/revenues ratio, and believes that a multiple of 10.5 times forecast 2002 revenue is appropriate..." Am I missing something here ? nig (disclaimer - I'm a shameless INCY long)

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next